Technology

Precision Molecular (PMI) is a clinical-stage company with the mission to develop imaging biomarkers and theranostics
(targeted therapy combined with diagnostics) for management of patients with CNS disorders and cancer.

PMI was founded in 2019 by Martin G. Pomper, M.D., Ph.D, Henry N. Wagner, Jr. Professor and Director of the Division of Nuclear
Medicine and Molecular Imaging at the Johns Hopkins School of Medicine. PMI’s foundational intellectual property was developed by
his world class radiology research team, known as the Precision Molecular Imaging Coalition.

PMI features various imaging biomarker products in the clinic with great potential to improve early diagnostics of neurodegenerative
diseases and cancer. Utilizing these imaging biomarkers to follow disease progression may provide clinical researchers with
powerful tools for early assessment of drug efficacy in clinical trials.

• Discussions with Leaders: A Conversation Between Martin Pomper and Peter Choyke. Journal of Nuclear Medicine. 61(1):3-5 (2020).
• Peptide-based PET quantifies target engagement of PD-L1 therapeutics. Journal of Clinical Investigation. 129(2):616-630 (2019).
• PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R). PNAS 116(5)1686-1691 (2019).
• Imaging of Glial Cell Activation and White Matter Integrity in Brains of Active and Recently Retired National Football League Players.
  JAMA Neurology 74(1):67-74 (2017).
• 18F-FNDP for PET Imaging of Soluble Epoxide Hydrolase. Journal of Molecular Imaging. 57(11)1817-1822 (2016).
• Biodistribution and Radiation Dosimetry of 124I-DPA-713, a PET Radiotracer for Macrophage-Associated Inflammation.
  Journal of Nuclear Medicine.

Technology

Theraly is a preclinical-stage company whose mission is to develop innovative treatments for various forms of
life-threatening fibrotic disease.

Theraly was founded in 2015 by Seulki Lee, PhD, Associate Professor of Radiology at the Johns Hopkins School of Medicine.
Theraly’s founding programs are based on the discoveries of Dr. Lee’s research team, whose pioneering research
has elucidated a TRAIL biology pathway underlying the origins of disease in tissue remodeling and fibrosis.
The company is focused on developing a potentially universal anti-fibrotic drug.

The lead asset TLY012, a human protein-based drug, selectively targets myofibroblasts, one of the significant
originators of fibrosis, and reverses established fibrosis in preclinical models of fibrosis in liver, pancreas, andskin.
TLY012 has the potential to cure fibrotic diseases, including systemic sclerosis, liver fibrosis/cirrhosis, and
chronic pancreatitis, as well as fibrosis driven cancers.

• Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma. Nature Communications 10:1128 (2019).
• Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells. Hepatology. 64(1):209-223 (2016).
• Paving the TRAIL to anti‐fibrotic therapy. Hepatology. 64(1):29-31 (2016).